miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis
Author(s): ,
Manuel Romero-Gómez
University of Seville, Seville, Spain
Corresponding author. Address: Digestive Diseases Unit, Virgen del Rocío University Hospital, Institute of Biomedicine of Seville, University of Seville, Avda Manuel Siurot s/n, Sevilla 41013, Spain. Tel.: +34 671535780; fax: +34 955 923 101.
Rocío Gallego-Durán
Institute of Biomedicine of Seville, Sevilla, Spain
Rocío Muñoz-Hernández
Institute of Biomedicine of Seville, Sevilla, Spain
Ángela Rojas
Institute of Biomedicine of Seville, Sevilla, Spain
Rocío Montero-Vallejo
University of Seville, Seville, Spain
Antonio Gil-Gómez
University of Seville, Seville, Spain
Javier Ampuero
University of Seville, Seville, Spain
Chang-Hai Liu
University of Seville, Seville, Spain
EASL LiverTree™. Romero Gomez M. Dec 1, 2018; 256774
Prof. Manuel Romero Gomez
Prof. Manuel Romero Gomez

Access to this content is an EASL members and LiverTree™ Privileged Users benefit.

Journal Abstract
Discussion Forum (0)
Rate & Comment (0)
Graphical abstract

Graphical abstract

miRNA-34a, miRNA-122 and miRNA-192 helped to distinguish NAFLD and NASH severity. The correlation of miRNA expression between serum and liver tissue was inconsistent. miRNA-122 showed moderate accuracy to distinguish NAFLD from healthy controls. miRNA-34a showed moderate accuracy to distinguish NASH from NAFL.

Background & Aims

microRNAs (miRNAs) are deregulated in non-alcoholic fatty liver disease (NAFLD) and have been proposed as useful markers for the diagnosis and stratification of disease severity. We conducted a meta-analysis to identify the potential usefulness of miRNA biomarkers in the diagnosis and stratification of NAFLD severity.


After a systematic review, circulating miRNA expression consistency and mean fold-changes were analysed using a vote-counting strategy. The sensitivity, specificity, positive and negative likelihood ratios, diagnostic odds ratio and area under the curve (AUC) for the diagnosis of NAFLD or non-alcoholic steatohepatitis (NASH) were pooled using a bivariate meta-analysis. Deeks’ funnel plot was used to assess the publication bias.


Thirty-seven studies of miRNA expression profiles and six studies of diagnostic accuracy were ultimately included in the quantitative analysis. miRNA-122 and miRNA-192 showed consistent upregulation. miRNA-122 was upregulated in every scenario used to distinguish NAFLD severity. The miRNA expression correlation between the serum and liver tissue was inconsistent across studies. miRNA-122 distinguished NAFLD from healthy controls with an AUC of 0.82 (95% CI 0.75–0.89), and miRNA-34a distinguished non-alcoholic steatohepatitis (NASH) from non-alcoholic fatty liver (NAFL) with an AUC of 0.78 (95% CI 0.67–0.88).


miRNA-34a, miRNA-122 and miRNA-192 were identified as potential diagnostic markers to segregate NAFL from NASH. Both miRNA-122, in distinguishing NAFLD from healthy controls, and miRNA-34a, in distinguishing NASH from NAFL, showed moderate diagnostic accuracy. miRNA-122 was upregulated in every scenario of NAFL, NASH and fibrosis.

Lay summary

microRNAs are deregulated in non-alcoholic fatty liver disease. The microRNAs, miRNA-34a, miRNA-122 and miRNA-192, were identified as potential biomarkers of non-alcoholic fatty liver and non-alcoholic steatohepatitis, at different stages of disease severity. The correlation between miRNA expression in the serum and in liver tissue was inconsistent, or even inverse.

Non-alcoholic fatty liver disease, miRNA, Expression profile, Diagnostic accuracy
[1]. M.A. Konerman - Pharmacotherapy for NASH: current and emerging
[2]. G. Cholankeril - Nonalcoholic fatty liver disease: epidemiology, natural history, and diagnostic challenges
[3]. S.A. Harrison - NASH, from diagnosis to treatment: where do we stand?
[4]. E.K. Spengler - Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
[5]. M. Blachier - The burden of liver disease in Europe: a review of available epidemiological data
[6]. S. Agrawal - Non-alcoholic fatty liver disease: east versus west
[7]. Q.M. Anstee - The genetics of NAFLD
[8]. M. Romero-Gomez - Treatment of NAFLD with diet, physical activity and exercise
[9]. E.T. Oni - A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?
[10]. S. De Minicis - From NAFLD to NASH and HCC: pathogenetic mechanisms and therapeutic insights
[11]. E. Fabbrini - Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications
[12]. A. Lonardo - Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups
[13]. R.J. Wong - Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States
[14]. N. Rafiq - Long-term follow-up of patients with nonalcoholic fatty liver
[15]. A.J. Sanyal - Endpoints and clinical trial design for nonalcoholic steatohepatitis
[16]. A.J. Sanyal - Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop
[17]. E.M. Brunt - Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings
[18]. D.E. Kleiner - Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children
[19]. M. Arrese - Circulating microRNAs: emerging biomarkers of liver disease
[20]. P.S. Mitchell - Circulating microRNAs as stable blood-based markers for cancer detection
[21]. M. Weiland - Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases
[22]. C.J. Pirola - Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis
[23]. D. Povero - Novel molecular mechanisms in the development of non-alcoholic steatohepatitis
[24]. K. Sato - Exosomes in liver pathology
[25]. D. Moher - Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
[26]. J.P.T. Higgins - Cochrane handbook for systematic reviews of interventions
[27]. P.F. Whiting - QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
[28]. O.L. Griffith - Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers
[29]. S.K. Chan - Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers
[30]. J.P. Higgins - Measuring inconsistency in meta-analyses
[31]. J.B. Reitsma - Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews
[32]. J.J. Deeks - The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed
[33]. O. Cheung - Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression
[34]. R. Gallego-Durán - P0969: Role of epigenetic factors in non-alcoholic steatohepatitis development
[35]. A.L. Simao - Mirna-339-3p is increased in human and experimental models of Nafld and targeted by Tudca in insulin-resistant muscle cells
[36]. N. Elfimova - 1255 miR-101 in steatosis and steatohepatitis of non-alcoholic fatty liver disease (NAFLD)
[37]. P. Handa - MicroRNA profiling in plasma of patients uncovers unique microRNA signatures associated with liver inflammation, cirrhosis, nonalcoholic steatohepatitis and hepatocellular carcinoma that predict the progression of Primary Sclerosing Cholangitis
[38]. Z.M. Younossi - Hepatic signature expression of miR-199a-5p, miR-21-3p, miR-224-5p, and miR-150-5p detected by NextSeq technology are independently associated with fibrosis in non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD)
[39]. R. Srivastava - Role of integrated microrna-mRNA network in human hepatic fat accumulation and non-alcoholic fatty liver disease
[40]. S. Cermelli - Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease
[41]. X.L. Liu - Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population
[42]. Y. Tan - A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease
[43]. H. Zhang - Serum levels of microRNAs can specifically predict liver injury of chronic hepatitis B
[44]. M. Celikbilek - Circulating microRNAs in patients with non-alcoholic fatty liver disease
[45]. C. Sun - MiR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR
[46]. B. Zhuge - MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator
[47]. Y. Guo - A micro-RNA expression signature for human NAFLD progression
[48]. R.E. Castro - MiR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease
[49]. D. Dattaroy - Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis
[50]. Y. Xu - A metabolic stress-inducible miR-34a-HNF4alpha pathway regulates lipid and lipoprotein metabolism
[51]. P.P. Becker - Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis
[52]. X. Loyer - Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARalpha expression
[53]. N.C. Salvoza - Association of circulating serum miR-34a and miR-122 with dyslipidemia among patients with non-alcoholic fatty liver disease
[54]. H. Yamada - Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver
[55]. G. Lendvai - Elevated miR-33a and miR-224 in steatotic chronic hepatitis C liver biopsies
[56]. T. Auguet - MiR33a/miR33b and miR122 as possible contributors to hepatic lipid metabolism in obese women with nonalcoholic fatty liver disease
[57]. P. Muangpaisarn - Serum microRNA-34a is potential biomarker for inflammation in nonalcoholic fatty liver disease
[58]. J. Latorre - Decreased lipid metabolism but increased FA biosynthesis are coupled with changes in liver microRNAs in obese subjects with NAFLD
[59]. D. Povero - Lipid-induced hepatocyte-derived extracellular vesicles regulate hepatic stellate cell via microRNAs targeting PPAR-gamma
[60]. I.P. Pogribny - Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice
[61]. T. Fu - Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor beta-Klotho
[62]. H. Xu - Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development
[63]. H. Miyaaki - Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease
[64]. I. Iino - Effect of miR-122 and its target gene cationic amino acid transporter 1 on colorectal liver metastasis
[65]. A.P. Lewis - Regulation and biological function of the liver-specific miR-122
[66]. C. Esau - MiR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
[67]. T. Babak - Probing microRNAs with microarrays: tissue specificity and functional inference
[68]. W. Filipowicz - The liver-specific microRNA miR-122: biology and therapeutic potential
[69]. M. Boeri - MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer
[70]. D. Povero - Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease
[71]. Y. Fu - Circulating microRNA-101 as a potential biomarker for hepatitis B virus-related hepatocellular carcinoma
[72]. T. Katsumi - Discrepant expression of mir-139-5p between serum and liver in patients with primary biliary cirrhosis, and its possible cellular origin
[73]. A. Krek - Combinatorial microRNA target predictions
[74]. M. Zhu - Integrated analysis of hepatic mRNA and miRNA profiles identified molecular networks and potential biomarkers of NAFLD
[75]. F. Sato - Intra-platform repeatability and inter-platform comparability of microRNA microarray technology
[76]. F. Leti - High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis
[77]. C.C. Pritchard - MicroRNA profiling: approaches and considerations
[78]. P. Mestdagh - A novel and universal method for microRNA RT-qPCR data normalization
[79]. J. Ampuero - Editorial: looking for patients at risk of cirrhosis in the general population-many needles in a haystack
[80]. M. Romero-Gomez - Detecting liver fat from viscoelasticity: how good is CAP in clinical practice? The need for universal cut-offs
[81]. L. Chang-Hai - Diagnostic accuracy of SCCA and SCCA-IgM for hepatocellular carcinoma: A meta-analysis
[82]. R. Ao - Altered microRNA-9 expression level is directly correlated with pathogenesis of nonalcoholic fatty liver disease by targeting Onecut2 and SIRT1
[83]. A. Zarrinpar - Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study
[84]. Y. Zhang - Upregulation of miR-15b in NAFLD models and in the serum of patients with fatty liver disease
[85]. J. Vega-Badillo - Hepatic miR-33a/miR-144 and their target gene ABCA1 are associated with steatohepatitis in morbidly obese subjects
[86]. K. Okamoto - A series of microRNA in the chromosome 14q32.2 maternally imprinted region related to progression of non-alcoholic fatty liver disease in a mouse model
[87]. Y. Wang - MiR-130a-3p attenuates activation and induces apoptosis of hepatic stellate cells in nonalcoholic fibrosing steatohepatitis by directly targeting TGFBR1 and TGFBR2
[88]. M. Lopez-Riera - New microRNA biomarkers for drug-induced steatosis and their potential to predict the contribution of drugs to non-alcoholic fatty liver disease
[89]. G. Hanin - MiRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression
[90]. M. Tran - Loss of miR-141/200c ameliorates hepatic steatosis and inflammation by reprogramming multiple signaling pathways in NASH
[91]. Q. Xu - MiRNA-103: molecular link between insulin resistance and nonalcoholic fatty liver disease
[92]. W. Yang - NFE2 induces miR-423-5p to promote gluconeogenesis and hyperglycemia by repressing the hepatic FAM3A-ATP-Akt pathway
[93]. L. Wang - Decreased MiR-155 level in the peripheral blood of non-alcoholic fatty liver disease patients may serve as a biomarker and may influence LXR activity
[94]. Y. Wang - MiR-181b regulates steatosis in nonalcoholic fatty liver disease via targeting SIRT1
[95]. S.C. Cazanave - A role for miR-296 in the regulation of lipoapoptosis by targeting PUMA
[96]. B. Li - Aberrant miR199a-5p/caveolin1/PPARalpha axis in hepatic steatosis
[97]. J. Guo - Reduced miR-200b and miR-200c expression contributes to abnormal hepatic lipid accumulation by stimulating JUN expression and activating the transcription of srebp1
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.

Save Settings